Scienture Holdings, Inc. — 2017 First-Quarter 10-Q Summary
Entity note: The supplied filing is for Trxade Group, Inc., not Scienture Holdings, Inc. Confirm that this is the intended filing before relying on this summary. The report covers the three months ended March 31, 2017; financial statements are unaudited.
Business context
Trxade operated a web-based marketplace connecting independent pharmacies with pharmaceutical suppliers. It reported more than 6,600 registered pharmacy members. The company sold its Westminster Pharmaceuticals distribution subsidiary in December 2016; the 2016 comparative results include Westminster as discontinued operations. Management said it was looking for opportunities to re-enter distribution.
Financial results and condition
| Metric | Q1 2017 | Q1 2016 or prior balance-sheet date |
|---|---|---|
| Revenue | $745,943 | $644,515 |
| Gross profit | $745,943 | $628,923 |
| Operating income (loss) | $141,450 | $(130,280) |
| Net income (loss), as presented in statements of operations | $79,726 | $(372,380), including discontinued operations |
| Net cash used in operating activities | $(48,283) | $(82,038) |
| Cash at period end | $169,996 | $14,679 at Dec. 31, 2016 |
| Total assets | $511,963 | $337,124 at Dec. 31, 2016 |
| Total liabilities | $1,237,907 | $1,485,181 at Dec. 31, 2016 |
| Shareholders’ deficit | $(725,944) | $(1,148,057) at Dec. 31, 2016 |
| Working capital | $(725,944) | $(1,137,470) at Dec. 31, 2016, per MD&A |
Revenue increased about 16% year over year. Reported gross margin was 100% in 2017 because cost of sales was zero, versus approximately 98% in 2016. Operating margin was approximately 19% in 2017, compared with an operating loss in the prior-year quarter. Net margin based on the statements of operations was approximately 11%. The filing does not provide a clear, reconciled net-income figure: the statements of operations report $79,726, while the EPS note reports $89,726 for 2017.
Financing activities provided $203,600, including $250,000 from a stock issuance, $250 from warrant exercises, and $46,650 of short-term note repayments. Cash increased by $155,317. Current liabilities included short-term notes and convertible payables; total current liabilities exceeded current assets by $725,944. The filing reports no investing cash flows.
Material changes, outlook and risks
- Management attributed revenue growth to increased platform fee income and transition fees related to the Westminster sale, and said its sales team continued adding customers through marketing and training.
- General and administrative expense declined, which management attributed in part to lower cash compensation. Executives suspended their salaries for six months beginning in January 2017.
- The company raised $250,000 through a January stock sale of 250,000 shares at $1.00 each, and issued warrants to buy 87,500 shares at $0.01 per share. The share issuance diluted existing holders.
- Management estimated approximately $2.425 million in general and administrative and working-capital requirements for the next 12 months. It expected to seek additional funding, but gave no assurance that financing would be available or operations would generate sufficient cash.
- The filing states that recurring operating losses and working-capital needs raise substantial doubt about the company’s ability to continue as a going concern. Management said additional capital and future profitable operations are necessary.
- In April 2017, the company repaid $165,000 of convertible notes plus $5,500 interest. It also extended other notes, with $181,500 due in May 2019 under revised terms. The filing separately describes a related-party note renewal in April.
- A $200,000 class-action settlement concerning alleged junk-fax advertising was approved and funded on March 17, 2017; it had been accrued at year-end 2016.
- Management reported that disclosure controls and procedures were not effective as of March 31, 2017. It reported no material change in internal control over financial reporting during the quarter.
- The filing reported no change in risk factors from the 2016 Form 10-K and no outstanding off-balance-sheet arrangements.
Important facts for investors to verify
- Whether this Trxade Group filing is actually the intended filing for the requested company, Scienture Holdings, Inc.
- The conflicting 2017 net-income amounts ($79,726 in the statements of operations versus $89,726 in the EPS note), and the differing interest-expense figures in the financial statements and MD&A.
- Cash runway and the company’s ability to meet its stated $2.425 million upcoming requirements, given negative working capital and management’s going-concern warning.
- Current status and terms of debt, including the April 2017 repayments, extensions, related-party obligations, and any further equity financing or dilution.
- Progress in growing platform revenue and customer activity following the Westminster sale, including whether transition fees recur.
- Remediation of ineffective disclosure controls and procedures.